{"transactions":[{"id":777896,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2026-05-15T20:08:01.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":5.04,"exercise_date":"2018-12-20","expiration_date":"2027-12-20","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0000882796-26-000021","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000021/form4.xml","form_type":"4"}},{"id":777895,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-15T20:08:01.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":62500,"price":9.54,"value":596250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":400703,"source":{"system":"sec-edgar","filing":"0000882796-26-000021","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000021/form4.xml","form_type":"4"}},{"id":777894,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-15T20:08:01.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":62500,"price":5.04,"value":315000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":463203,"source":{"system":"sec-edgar","filing":"0000882796-26-000021","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000021/form4.xml","form_type":"4"}},{"id":835913,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2026-03-18T20:11:09.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000882796-26-000015","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000015/form4.xml","form_type":"4"}},{"id":835912,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:09.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":150000,"price":9.15,"value":1372500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":400703,"source":{"system":"sec-edgar","filing":"0000882796-26-000015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000015/form4.xml","form_type":"4"}},{"id":835911,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:11:09.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":true,"shares":150000,"price":5.51,"value":826500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":550703,"source":{"system":"sec-edgar","filing":"0000882796-26-000015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000015/form4.xml","form_type":"4"}},{"id":960273,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-23T21:11:38.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":21773,"price":7.65,"value":166563.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":398751,"source":{"system":"sec-edgar","filing":"0000882796-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000043/form4.xml","form_type":"4"}},{"id":960272,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-23T21:11:38.000Z","date":"2025-12-19","kind":"tax_withholding","planned":true,"acquired":false,"shares":16902,"price":7.41,"value":125243.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person."}],"balance_after":420524,"source":{"system":"sec-edgar","filing":"0000882796-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000043/form4.xml","form_type":"4"}},{"id":962574,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2025-12-19T21:17:34.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":255050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":255050,"derivative":{"exercise_price":7.13,"exercise_date":"2026-12-17","expiration_date":"2035-12-17","underlying":"Common Stock","underlying_shares":255050},"source":{"system":"sec-edgar","filing":"0001171843-25-008037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325008037/ownership.xml","form_type":"4"}},{"id":962573,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:17:34.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":121700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":437426,"source":{"system":"sec-edgar","filing":"0001171843-25-008037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325008037/ownership.xml","form_type":"4"}},{"id":968341,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:13:10.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":21210,"price":7.65,"value":162256.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":315726,"source":{"system":"sec-edgar","filing":"0000882796-25-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000033/form4.xml","form_type":"4"}},{"id":968340,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:13:10.000Z","date":"2025-12-12","kind":"tax_withholding","planned":true,"acquired":false,"shares":8540,"price":7.57,"value":64647.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person."}],"balance_after":336936,"source":{"system":"sec-edgar","filing":"0000882796-25-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000033/form4.xml","form_type":"4"}},{"id":982626,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2025-12-03T23:40:53.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":false,"shares":91004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":91004},"source":{"system":"sec-edgar","filing":"0000882796-25-000027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000027/form4.xml","form_type":"4"}},{"id":982625,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-03T23:40:53.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":19770,"price":7.65,"value":151240.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":345476,"source":{"system":"sec-edgar","filing":"0000882796-25-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000027/form4.xml","form_type":"4"}},{"id":982624,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-03T23:40:53.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":50906,"price":7.2136,"value":367215.5216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":365246,"source":{"system":"sec-edgar","filing":"0000882796-25-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000027/form4.xml","form_type":"4"}},{"id":982623,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-03T23:40:53.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":91004,"price":7.1042,"value":646510.6168,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":416152,"source":{"system":"sec-edgar","filing":"0000882796-25-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000027/form4.xml","form_type":"4"}},{"id":982622,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-03T23:40:53.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":true,"shares":91004,"price":3.22,"value":293032.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":507156,"source":{"system":"sec-edgar","filing":"0000882796-25-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000027/form4.xml","form_type":"4"}},{"id":1323461,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2024-12-23T21:05:25.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":250100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":250100,"derivative":{"exercise_price":7.39,"exercise_date":"2025-12-19","expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":250100},"source":{"system":"sec-edgar","filing":"0001127602-24-029952","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029952/form4.xml","form_type":"4"}},{"id":1323460,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-12-23T21:05:25.000Z","date":"2024-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":2461,"price":7.39,"value":18186.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":412729,"source":{"system":"sec-edgar","filing":"0001127602-24-029952","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029952/form4.xml","form_type":"4"}},{"id":1323459,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-12-23T21:05:25.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":120700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":415190,"source":{"system":"sec-edgar","filing":"0001127602-24-029952","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029952/form4.xml","form_type":"4"}},{"id":1329828,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-12-17T21:10:26.000Z","date":"2024-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":8613,"price":7.53,"value":64855.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":294490,"source":{"system":"sec-edgar","filing":"0001127602-24-029582","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029582/form4.xml","form_type":"4"}},{"id":1516574,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-15T11:11:17.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.53,"value":27650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.36 to $5.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":300762,"source":{"system":"sec-edgar","filing":"0001127602-24-015367","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224015367/form4.xml","form_type":"4"}},{"id":1703748,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:33:27.000Z","date":"2023-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":2482,"price":6.05,"value":15016.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":293539,"source":{"system":"sec-edgar","filing":"0001127602-23-030177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223030177/form4.xml","form_type":"4"}},{"id":1708108,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2023-12-18T21:34:30.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":158500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":158500,"derivative":{"exercise_price":6.43,"exercise_date":"2024-12-14","expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":158500},"source":{"system":"sec-edgar","filing":"0001127602-23-029829","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029829/form4.xml","form_type":"4"}},{"id":1708107,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:34:30.000Z","date":"2023-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":4015,"price":6.43,"value":25816.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":296021,"source":{"system":"sec-edgar","filing":"0001127602-23-029829","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029829/form4.xml","form_type":"4"}},{"id":1708106,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:34:30.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":300036,"source":{"system":"sec-edgar","filing":"0001127602-23-029829","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029829/form4.xml","form_type":"4"}},{"id":2079149,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-21T21:43:15.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":158500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":158500,"derivative":{"exercise_price":10.63,"exercise_date":"2023-12-19","expiration_date":"2032-12-19","underlying":"Common Stock","underlying_shares":158500},"source":{"system":"sec-edgar","filing":"0001127602-22-028084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028084/form4.xml","form_type":"4"}},{"id":2079148,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:43:15.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":232770,"source":{"system":"sec-edgar","filing":"0001127602-22-028084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028084/form4.xml","form_type":"4"}},{"id":2082607,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-12-19T21:38:16.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":4175,"price":10.88,"value":45424.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 13,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":198770,"source":{"system":"sec-edgar","filing":"0001127602-22-027858","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222027858/form4.xml","form_type":"4"}},{"id":2436228,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-13T21:36:00.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error.  This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date."}],"balance_after":201969,"source":{"system":"sec-edgar","filing":"0001127602-22-001452","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222001452/form4a.xml","form_type":"4/A","original_submission_date":"2021-12-16"}},{"id":2470717,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-16T22:03:30.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":164000,"derivative":{"exercise_price":11.43,"exercise_date":"2022-12-14","expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0001127602-21-031126","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031126/form4.xml","form_type":"4"}},{"id":2470716,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-12-16T22:03:30.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":221969,"source":{"system":"sec-edgar","filing":"0001127602-21-031126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031126/form4.xml","form_type":"4"}},{"id":2715377,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-12","kind":"exercise","acquired":false,"shares":35852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares."}],"balance_after":0,"derivative":{"exercise_price":4.73,"exercise_date":"2013-03-01","expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":35852},"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715376,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.45,"expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715375,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":33132,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":33132},"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715374,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":1648,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35852,"derivative":{"exercise_price":4.73,"exercise_date":"2013-03-01","expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":1648},"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715373,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-12","kind":"exercise","acquired":true,"shares":35852,"price":4.73,"value":169579.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares."}],"balance_after":146127,"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715372,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":102780,"price":12.04,"value":1237471.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":110275,"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715371,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":68000,"price":5.45,"value":370600.0,"ownership":{"direct":true},"balance_after":213055,"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715370,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":33132,"price":1.42,"value":47047.44,"ownership":{"direct":true},"balance_after":145055,"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2715369,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:43:13.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":1648,"price":4.73,"value":7795.04,"ownership":{"direct":true},"balance_after":111923,"source":{"system":"sec-edgar","filing":"0001127602-21-016587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016587/form4.xml","form_type":"4"}},{"id":2941057,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-17T21:32:54.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":280000,"derivative":{"exercise_price":8.31,"exercise_date":"2021-12-15","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001127602-20-031791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031791/form4.xml","form_type":"4"}},{"id":2945385,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-15T22:35:26.000Z","date":"2020-12-11","kind":"exercise","acquired":false,"shares":13741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."}],"balance_after":0,"derivative":{"exercise_price":4.15,"exercise_date":"2012-03-01","expiration_date":"2021-03-01","underlying":"Common Stock","underlying_shares":13741},"source":{"system":"sec-edgar","filing":"0001127602-20-031406","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031406/form4.xml","form_type":"4"}},{"id":2945384,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-15T22:35:26.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":13741,"price":7.96,"value":109378.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.97. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":108061,"source":{"system":"sec-edgar","filing":"0001127602-20-031406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031406/form4.xml","form_type":"4"}},{"id":2945383,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-15T22:35:26.000Z","date":"2020-12-11","kind":"exercise","acquired":true,"shares":13741,"price":4.15,"value":57025.15,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."}],"balance_after":121802,"source":{"system":"sec-edgar","filing":"0001127602-20-031406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031406/form4.xml","form_type":"4"}},{"id":2954285,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-08T21:12:33.000Z","date":"2020-12-04","kind":"exercise","acquired":false,"shares":13741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."}],"balance_after":13741,"derivative":{"exercise_price":4.15,"exercise_date":"2012-03-01","expiration_date":"2021-03-01","underlying":"Common Stock","underlying_shares":13741},"source":{"system":"sec-edgar","filing":"0001127602-20-030837","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030837/form4.xml","form_type":"4"}},{"id":2954284,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-08T21:12:33.000Z","date":"2020-12-04","kind":"sale","acquired":false,"shares":13741,"price":6.23,"value":85606.43,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.22 to $6.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":108061,"source":{"system":"sec-edgar","filing":"0001127602-20-030837","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030837/form4.xml","form_type":"4"}},{"id":2954283,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-08T21:12:33.000Z","date":"2020-12-04","kind":"exercise","acquired":true,"shares":13741,"price":4.15,"value":57025.15,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."}],"balance_after":121802,"source":{"system":"sec-edgar","filing":"0001127602-20-030837","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030837/form4.xml","form_type":"4"}},{"id":2955698,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-07T21:21:17.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020."}],"balance_after":17000,"derivative":{"exercise_price":5.45,"exercise_date":"2020-12-03","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001127602-20-030700","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030700/form4.xml","form_type":"4"}},{"id":3250618,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-25T21:44:59.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":12400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested."}],"balance_after":12400,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-21","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":12400},"source":{"system":"sec-edgar","filing":"0001127602-20-007677","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220007677/form4.xml","form_type":"4"}},{"id":3264773,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-19T22:11:11.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":21700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested."}],"balance_after":21700,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-14","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":21700},"source":{"system":"sec-edgar","filing":"0001127602-20-006505","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220006505/form4.xml","form_type":"4"}},{"id":3335650,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-12-19T22:55:05.000Z","date":"2019-12-17","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":190000,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-17","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001127602-19-035553","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219035553/form4.xml","form_type":"4"}},{"id":3369155,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-11-18T21:05:19.000Z","date":"2019-11-18","kind":"purchase","acquired":true,"shares":20000,"price":1.45,"value":29000.0,"ownership":{"direct":true},"balance_after":102061,"source":{"system":"sec-edgar","filing":"0001127602-19-033008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219033008/form4.xml","form_type":"4"}},{"id":3710946,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-01-03T21:38:54.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":423,"price":8.07,"value":3413.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":77530,"source":{"system":"sec-edgar","filing":"0001127602-19-000736","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219000736/form4.xml","form_type":"4"}},{"id":3722653,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-21T21:15:12.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":190000,"derivative":{"exercise_price":7.06,"exercise_date":"2019-12-20","expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001127602-18-037182","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218037182/form4.xml","form_type":"4"}},{"id":3744928,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-04T21:11:14.000Z","date":"2018-11-30","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001127602-18-035081","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035081/form4.xml","form_type":"4"}},{"id":3744927,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-12-04T21:11:14.000Z","date":"2018-11-30","kind":"sale","acquired":false,"shares":44290,"price":9.07,"value":401710.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.00 to $9.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":77953,"source":{"system":"sec-edgar","filing":"0001127602-18-035081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035081/form4.xml","form_type":"4"}},{"id":3744926,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"Senior VP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-12-04T21:11:14.000Z","date":"2018-11-30","kind":"exercise","acquired":true,"shares":25000,"price":1.42,"value":35500.0,"ownership":{"direct":true},"balance_after":122243,"source":{"system":"sec-edgar","filing":"0001127602-18-035081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035081/form4.xml","form_type":"4"}},{"id":3929330,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-05-17T13:25:42.000Z","date":"2018-05-15","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8132,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001127602-18-017800","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218017800/form4.xml","form_type":"4"}},{"id":3929329,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2018-05-17T13:25:42.000Z","date":"2018-05-15","kind":"tax_withholding","acquired":false,"shares":3004,"price":5.91,"value":17753.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise."}],"balance_after":95264,"source":{"system":"sec-edgar","filing":"0001127602-18-017800","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218017800/form4.xml","form_type":"4"}},{"id":3929328,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2018-05-17T13:25:42.000Z","date":"2018-05-15","kind":"exercise","acquired":true,"shares":12500,"price":1.42,"value":17750.0,"ownership":{"direct":true},"balance_after":98268,"source":{"system":"sec-edgar","filing":"0001127602-18-017800","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218017800/form4.xml","form_type":"4"}},{"id":4021927,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-03-02T19:21:05.000Z","date":"2018-02-28","kind":"exercise","acquired":false,"shares":6709,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.26,"exercise_date":"2009-03-14","expiration_date":"2018-03-14","underlying":"Common Stock","underlying_shares":6709},"source":{"system":"sec-edgar","filing":"0001127602-18-009566","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218009566/form4.xml","form_type":"4"}},{"id":4021926,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2018-03-02T19:21:05.000Z","date":"2018-02-28","kind":"exercise","acquired":true,"shares":6709,"price":3.26,"value":21871.34,"ownership":{"direct":true},"balance_after":85768,"source":{"system":"sec-edgar","filing":"0001127602-18-009566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218009566/form4.xml","form_type":"4"}},{"id":4092903,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2018-01-23T14:12:47.000Z","date":"2018-01-20","kind":"tax_withholding","acquired":false,"shares":1961,"price":5.59,"value":10961.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014."}],"balance_after":77129,"source":{"system":"sec-edgar","filing":"0001127602-18-002237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218002237/form4.xml","form_type":"4"}},{"id":4114668,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2018-01-03T14:13:25.000Z","date":"2018-01-01","kind":"tax_withholding","acquired":false,"shares":459,"price":4.91,"value":2253.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":79090,"source":{"system":"sec-edgar","filing":"0001127602-18-000308","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218000308/form4.xml","form_type":"4"}},{"id":4122961,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-12-22T15:16:58.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":62500,"derivative":{"exercise_price":5.04,"exercise_date":"2018-12-20","expiration_date":"2027-12-20","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001127602-17-035406","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217035406/form4.xml","form_type":"4"}},{"id":4218737,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-09-05T19:43:29.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":18600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017."}],"balance_after":18600,"derivative":{"exercise_price":11.13,"exercise_date":"2017-08-31","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0001127602-17-026942","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217026942/form4.xml","form_type":"4"}},{"id":4415598,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-03-01T18:53:03.000Z","date":"2017-02-27","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001127602-17-009101","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217009101/form4.xml","form_type":"4"}},{"id":4483411,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2017-01-24T14:28:01.000Z","date":"2017-01-20","kind":"tax_withholding","acquired":false,"shares":2599,"price":5.95,"value":15464.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014."}],"balance_after":75497,"source":{"system":"sec-edgar","filing":"0001127602-17-002252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217002252/form4.xml","form_type":"4"}},{"id":4508849,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2017-01-03T19:13:48.000Z","date":"2017-01-01","kind":"tax_withholding","acquired":false,"shares":1281,"price":6.33,"value":8108.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015."}],"balance_after":78096,"source":{"system":"sec-edgar","filing":"0001127602-17-000087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217000087/form4.xml","form_type":"4"}},{"id":4602039,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":47066,"kind":"person","name":"Barnes Alane P","position":1,"cik":"0001584348","reported_name":"Barnes Alane P","relationship":{"officer":true,"officer_title":"VP, General Counsel & Corp Sec"}}],"security":"Common Stock","published_at":"2016-09-16T14:54:26.000Z","date":"2016-09-14","kind":"sale","acquired":false,"shares":8357,"price":4.27,"value":35684.39,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.22 to $4.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":79377,"source":{"system":"sec-edgar","filing":"0001127602-16-062585","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760216062585/form4.xml","form_type":"4"}}]}